When anti-EGFR antibody is used in pharmacotherapy, hypomagnesemia is an adverse effect that is relatively common; it should be treated with caution since when it is severe, it can lead to arrhythmia. This evidence concerns the gene EGFR and familial primary hypomagnesemia.